Real-World Evidence (RWE) and the Chinese Regulatory Landscape

adicionou um novo artigo Aura & Çakra

2026-02-02 13:14:04 -

The Center for Drug Evaluation (CDE) in China has increasingly recognized the value of Real-World Evidence (RWE) in the drug approval and post-market surveillance process. This regulatory shift is transforming how domestic and international pharmaceutical companies operate within the Chinese market. Clinical data analytics is now being used to supplement traditional clinical trial data, helping...

0 Comentários 0 Compartilhamentos 454 Visualizações 0 Anterior